Category Archives: Testosterone

ReportLinker

Abstract: What`s New for 2022? Global competitiveness and key competitor percentage market shares. Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hormone Replacement Therapy (HRT) Industry" - https://www.reportlinker.com/p05961363/?utm_source=GNW Online interactive peer-to-peer collaborative bespoke updatesAccess to our digital archives and MarketGlass Research PlatformComplimentary updates for one year

Global Hormone Replacement Therapy (HRT) Market to Reach $40.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Hormone Replacement Therapy (HRT) estimated at US$26.6 Billion in the year 2020, is projected to reach a revised size of US$40.5 Billion by 2027, growing at a CAGR of 6.2% over the analysis period 2020-2027. Estrogen Hormone Replacement Therapy, one of the segments analyzed in the report, is projected to record a 6.3% CAGR and reach US$22.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Human Growth Hormone Replacement Therapy segment is readjusted to a revised 7.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $7.8 Billion, While China is Forecast to Grow at 5.8% CAGR

The Hormone Replacement Therapy (HRT) market in the U.S. is estimated at US$7.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.1 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 4.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Testosterone Hormone Replacement Therapy Segment to Record 5.3% CAGR

In the global Testosterone Hormone Replacement Therapy segment, USA, Canada, Japan, China and Europe will drive the 5.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3.7 Billion in the year 2020 will reach a projected size of US$5.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$4.7 Billion by the year 2027.

Select Competitors (Total 47 Featured) - Abbott LaboratoriesAllergan PlcBayer AGNovartis AGNoven Pharmaceuticals Inc.Novo Nordisk A/SPfizer Inc.TherapeuticsMD Inc.

Read the full report: https://www.reportlinker.com/p05961363/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEWInfluencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global RecessionAn Introduction to Menopause and Hormone Replacement TherapyRecent Market ActivityThe HRT Controversy - An InsightNewer Studies Challenge WHI Findings and Re-establish Safety ofHRTRevised Recommendations of the NAMS and Endocrine SocietyIMS Consensus Guidelines Paving Way for More Clarity of HRTThe Regional DivideIncreasing Number of Menopausal Women - A Major Market DriverNew Bioidentical Drugs Serve Unmet Market NeedsGeneric Incursion in Hormone Replacement Therapy - List ofDrugs With and Without Approved Generic VersionsIntense Competition Marks the Global HRT MarketThe Premarin SagaEstrace Cream Drives Revenue Gains in Allergan?s HRT PortfolioHormone Replacement Therapy (HRT) - Global Key CompetitorsPercentage Market Share in 2022 (E)Competitive Market Presence - Strong/Active/Niche/Trivial forPlayers Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERSAbbott Laboratories (USA)Allergan Plc (Ireland)Bayer AG (Germany)Noven Pharmaceuticals, Inc. (USA)Novartis AG(Switzerland)Novo Nordisk A/S (Denmark)Orion Pharma AB (Finland)Pfizer, Inc. (USA)TherapeuticsMD, Inc. (USA)

3. MARKET TRENDS & DRIVERSUnmet Needs in Combination Therapies for HRT drive Research forNew MedicinesTopical Estrogens - More Safe and EffectiveTransdermal HRT Products Present Exciting OpportunitiesPhytoestrogens - The New Panacea for Menopausal Symptoms?Diet Link to Menopause Symptoms Raises InterestImpact of Soy and Other Phytoestrogens - A Reality CheckEstroG - A Successful Herbal Health Supplement in AlleviatingMenopausal SymptomsThe Growing Buzz around Bioidentical DrugsBio-identical Hormones - A Natural and Safe Substitute toSynthetic HRT?Pellet Therapy - A New Innovation Downsizes Conventional Issueswith Bioidentical HRTDirect-to-Consumer Advertising for HRT - A Mixed BagEstriol: The Next Generation Estrogen Therapy?What Makes Estriol Work?Topical Estriol - More Promising in SafetyEstriol - Used More Commonly Outside the USEntry of Generics Threatens Market Growth ProspectsAre Non-Hormonal Therapies A Threat to HRT?Earlier Failures Induce Lethargy in Non-Hormonal Therapies

4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Geographic Region - USA,Canada, Japan, China, Europe, Asia-Pacific and Rest of WorldMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Hormone Replacement Therapy(HRT) by Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2019 and% CAGR

Table 3: World 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Geographic Region - Percentage Breakdown ofValue Sales for USA, Canada, Japan, China, Europe, Asia-Pacificand Rest of World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis forEstrogen Hormone Replacement Therapy by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets - Independent Analysis of Annual Sales in US$Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Estrogen Hormone ReplacementTherapy by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2012 through2019 and % CAGR

Table 6: World 15-Year Perspective for Estrogen HormoneReplacement Therapy by Geographic Region - Percentage Breakdownof Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for HumanGrowth Hormone Replacement Therapy by Geographic Region - USA,Canada, Japan, China, Europe, Asia-Pacific and Rest of WorldMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Human Growth HormoneReplacement Therapy by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Million for Years2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Human Growth HormoneReplacement Therapy by Geographic Region - Percentage Breakdownof Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis forTestosterone Hormone Replacement Therapy by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets - Independent Analysis of Annual Sales in US$Million for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Testosterone HormoneReplacement Therapy by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Million for Years2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Testosterone HormoneReplacement Therapy by Geographic Region - Percentage Breakdownof Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis forThyroid Hormone Replacement Therapy by Geographic Region - USA,Canada, Japan, China, Europe, Asia-Pacific and Rest of WorldMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Thyroid Hormone ReplacementTherapy by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2012 through2019 and % CAGR

Table 15: World 15-Year Perspective for Thyroid HormoneReplacement Therapy by Geographic Region - Percentage Breakdownof Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis forMenopause by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2020 through2027 and % CAGR

Table 17: World Historic Review for Menopause by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Menopause by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World for Years2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for MaleHypogonadism by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2020 through2027 and % CAGR

Table 20: World Historic Review for Male Hypogonadism byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2019 and% CAGR

Table 21: World 15-Year Perspective for Male Hypogonadism byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis forGrowth Hormone Deficiency by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Million for Years2020 through 2027 and % CAGR

Table 23: World Historic Review for Growth Hormone Deficiencyby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2019 and% CAGR

Table 24: World 15-Year Perspective for Growth HormoneDeficiency by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis forHypothyroidism by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Million for Years2020 through 2027 and % CAGR

Table 26: World Historic Review for Hypothyroidism byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2019 and% CAGR

Table 27: World 15-Year Perspective for Hypothyroidism byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis forOther Type of Diseases by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Million for Years2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Type of Diseases byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2019 and% CAGR

Table 30: World 15-Year Perspective for Other Type of Diseasesby Geographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2021 & 2027

Table 31: World Hormone Replacement Therapy (HRT) MarketAnalysis of Annual Sales in US$ Million for Years 2012 through2027

III. MARKET ANALYSIS

UNITED STATESHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Statesfor 2022 (E)Table 32: USA Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 33: USA Historic Review for Hormone Replacement Therapy(HRT) by Product - Estrogen Hormone Replacement Therapy, HumanGrowth Hormone Replacement Therapy, Testosterone HormoneReplacement Therapy and Thyroid Hormone Replacement TherapyMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 34: USA 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 35: USA Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 36: USA Historic Review for Hormone Replacement Therapy(HRT) by Type of Disease - Menopause, Male Hypogonadism, GrowthHormone Deficiency, Hypothyroidism and Other Type of DiseasesMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 37: USA 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

CANADATable 38: Canada Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 39: Canada Historic Review for Hormone ReplacementTherapy (HRT) by Product - Estrogen Hormone ReplacementTherapy, Human Growth Hormone Replacement Therapy, TestosteroneHormone Replacement Therapy and Thyroid Hormone ReplacementTherapy Markets - Independent Analysis of Annual Sales in US$Million for Years 2012 through 2019 and % CAGR

Table 40: Canada 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 41: Canada Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 42: Canada Historic Review for Hormone ReplacementTherapy (HRT) by Type of Disease - Menopause, MaleHypogonadism, Growth Hormone Deficiency, Hypothyroidism andOther Type of Diseases Markets - Independent Analysis of AnnualSales in US$ Million for Years 2012 through 2019 and % CAGR

Table 43: Canada 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

JAPANHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)Table 44: Japan Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 45: Japan Historic Review for Hormone Replacement Therapy(HRT) by Product - Estrogen Hormone Replacement Therapy, HumanGrowth Hormone Replacement Therapy, Testosterone HormoneReplacement Therapy and Thyroid Hormone Replacement TherapyMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 46: Japan 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 47: Japan Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 48: Japan Historic Review for Hormone Replacement Therapy(HRT) by Type of Disease - Menopause, Male Hypogonadism, GrowthHormone Deficiency, Hypothyroidism and Other Type of DiseasesMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 49: Japan 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

CHINAHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)Table 50: China Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 51: China Historic Review for Hormone Replacement Therapy(HRT) by Product - Estrogen Hormone Replacement Therapy, HumanGrowth Hormone Replacement Therapy, Testosterone HormoneReplacement Therapy and Thyroid Hormone Replacement TherapyMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 52: China 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 53: China Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 54: China Historic Review for Hormone Replacement Therapy(HRT) by Type of Disease - Menopause, Male Hypogonadism, GrowthHormone Deficiency, Hypothyroidism and Other Type of DiseasesMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 55: China 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

EUROPEHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)Table 56: Europe Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Geographic Region -France, Germany, Italy, UK and Rest of Europe Markets -Independent Analysis of Annual Sales in US$ Million for Years2020 through 2027 and % CAGR

Table 57: Europe Historic Review for Hormone ReplacementTherapy (HRT) by Geographic Region - France, Germany, Italy, UKand Rest of Europe Markets - Independent Analysis of AnnualSales in US$ Million for Years 2012 through 2019 and % CAGR

Table 58: Europe 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Geographic Region - Percentage Breakdown ofValue Sales for France, Germany, Italy, UK and Rest of EuropeMarkets for Years 2012, 2021 & 2027

Table 59: Europe Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 60: Europe Historic Review for Hormone ReplacementTherapy (HRT) by Product - Estrogen Hormone ReplacementTherapy, Human Growth Hormone Replacement Therapy, TestosteroneHormone Replacement Therapy and Thyroid Hormone ReplacementTherapy Markets - Independent Analysis of Annual Sales in US$Million for Years 2012 through 2019 and % CAGR

Table 61: Europe 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 62: Europe Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 63: Europe Historic Review for Hormone ReplacementTherapy (HRT) by Type of Disease - Menopause, MaleHypogonadism, Growth Hormone Deficiency, Hypothyroidism andOther Type of Diseases Markets - Independent Analysis of AnnualSales in US$ Million for Years 2012 through 2019 and % CAGR

Table 64: Europe 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

FRANCEHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)Table 65: France Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 66: France Historic Review for Hormone ReplacementTherapy (HRT) by Product - Estrogen Hormone ReplacementTherapy, Human Growth Hormone Replacement Therapy, TestosteroneHormone Replacement Therapy and Thyroid Hormone ReplacementTherapy Markets - Independent Analysis of Annual Sales in US$Million for Years 2012 through 2019 and % CAGR

Table 67: France 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 68: France Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 69: France Historic Review for Hormone ReplacementTherapy (HRT) by Type of Disease - Menopause, MaleHypogonadism, Growth Hormone Deficiency, Hypothyroidism andOther Type of Diseases Markets - Independent Analysis of AnnualSales in US$ Million for Years 2012 through 2019 and % CAGR

Table 70: France 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

GERMANYHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)Table 71: Germany Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 72: Germany Historic Review for Hormone ReplacementTherapy (HRT) by Product - Estrogen Hormone ReplacementTherapy, Human Growth Hormone Replacement Therapy, TestosteroneHormone Replacement Therapy and Thyroid Hormone ReplacementTherapy Markets - Independent Analysis of Annual Sales in US$Million for Years 2012 through 2019 and % CAGR

Table 73: Germany 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 74: Germany Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 75: Germany Historic Review for Hormone ReplacementTherapy (HRT) by Type of Disease - Menopause, MaleHypogonadism, Growth Hormone Deficiency, Hypothyroidism andOther Type of Diseases Markets - Independent Analysis of AnnualSales in US$ Million for Years 2012 through 2019 and % CAGR

Table 76: Germany 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

ITALYTable 77: Italy Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Table 78: Italy Historic Review for Hormone Replacement Therapy(HRT) by Product - Estrogen Hormone Replacement Therapy, HumanGrowth Hormone Replacement Therapy, Testosterone HormoneReplacement Therapy and Thyroid Hormone Replacement TherapyMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 79: Italy 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Product - Percentage Breakdown of Value Salesfor Estrogen Hormone Replacement Therapy, Human Growth HormoneReplacement Therapy, Testosterone Hormone Replacement Therapyand Thyroid Hormone Replacement Therapy for the Years 2012,2021 & 2027

Table 80: Italy Recent Past, Current & Future Analysis forHormone Replacement Therapy (HRT) by Type of Disease -Menopause, Male Hypogonadism, Growth Hormone Deficiency,Hypothyroidism and Other Type of Diseases - IndependentAnalysis of Annual Sales in US$ Million for the Years 2020through 2027 and % CAGR

Table 81: Italy Historic Review for Hormone Replacement Therapy(HRT) by Type of Disease - Menopause, Male Hypogonadism, GrowthHormone Deficiency, Hypothyroidism and Other Type of DiseasesMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2012 through 2019 and % CAGR

Table 82: Italy 15-Year Perspective for Hormone ReplacementTherapy (HRT) by Type of Disease - Percentage Breakdown ofValue Sales for Menopause, Male Hypogonadism, Growth HormoneDeficiency, Hypothyroidism and Other Type of Diseases for theYears 2012, 2021 & 2027

UNITED KINGDOMHormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdomfor 2022 (E)Table 83: UK Recent Past, Current & Future Analysis for HormoneReplacement Therapy (HRT) by Product - Estrogen HormoneReplacement Therapy, Human Growth Hormone Replacement Therapy,Testosterone Hormone Replacement Therapy and Thyroid HormoneReplacement Therapy - Independent Analysis of Annual Sales inUS$ Million for the Years 2020 through 2027 and % CAGR

Read more:
Global Hormone Replacement Therapy (HRT) Market to Reach $40.5 Billion by 2027 - Yahoo Finance UK

Therapeutic developments have been aimed at enhancing outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC), an aggressive form of prostate cancer that may rapidly become castration resistant.1 Advances in the understanding of the genomics and biological functions of prostate cancer have resulted in the emergence of several new classes of agents that have improved outcomes in men with prostate cancer, including mHSPC.1 For example, several next-generation androgen receptor (AR) signaling inhibitors have recently received expanded FDA approval to include treatment of men with mHSPC.1-5

Although clinicians have welcomed the addition of novel AR-targeted agents to the mHSPC management arsenal, they have also faced the conundrum of how to best select among them when treatment intensification is needed.

During a recent OncLive Peer Exchange, panel of experts in genitourinary cancer provided an overview of the FDA-approved novel AR-targeted agents for mHSPC, including the pivotal trials that led to their approval. They also shared the factors they consider when selecting among these agents and the rationale for using triplet therapy in some patient subgroups with mHSPC.

Targeting the androgen-signaling axis remains the most effective strategy for treating patients with prostate cancer, which can encompass multiple approaches, including targeting gonadotropin-releasing hormone to prevent release of luteinizing hormone, targeting cytochrome P450 (CYP) 17A1 to restrain androgen synthesis, and directly targeting AR transcriptional activity.1 Four AR-targeted therapies have received approval for the treatment of patients with mHSPC (Table).2-9 Of these treatments, abiraterone acetate (Zytiga) targets CYP17A1, and darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) target AR transcriptional activity.1

Darolutamide is the latest AR-targeted therapy to receive expanded indication for the treatment of men with mHSPC.2 Approval for this indication was based on data from the phase 3 ARASENS trial (NCT02799602), which randomly assigned 1306 patients with mHSPC to receive darolutamide 600 mg orally twice daily plus docetaxel 75 mg/m2 intravenously every 3 weeks for up to 6 cycles (n = 651) or docetaxel plus placebo (n = 655).10 The primary end point was overall survival (OS), which was assessed in the primary analysis after 533 patients had died (229 in the darolutamide arm and 304 in the placebo arm).

The primary analysis showed a 32.5% lower risk of death in the darolutamide arm vs the placebo arm (HR, 0.68; 95% CI, 0.57-0.80; P < .001). At 4 years, the OS was 62.7% (95% CI, 58.7-66.7) in the darolutamide arm and 50.4% (95% CI, 46.3-54.6) in the placebo arm. Additionally, darolutamide was associated with significantly greater benefits than placebo for several secondary endpoints, including time to castration-resistant prostate cancer, time to pain progression, symptomatic skeletal eventfree survival, time to first symptomatic skeletal events, and time to initiation of subsequent systemic antineoplastic therapy.10

The FDA approval of enzalutamide for mHSPC was based on data from the phase 3 ARCHES trial (NCT02677896), which randomly assigned 1150 patients with mHSPC to receive enzalutamide plus androgen deprivation therapy (ADT) or placebo plus ADT. Patients were stratified by disease volume and prior docetaxel chemotherapy. The studys primary end point was radiographic progression-free survival (rPFS).

In the ARCHES trial, we showed that enzalutamide delays rPFS, which led to the FDA approval of that therapy, said Andrew J. Armstrong, MD, MSc, who was an ARCHES study investigator. Radiographic progression or death was reduced by 61% in the enzalutamide plus ADT arm vs the placebo plus ADT arm (HR, 0.39; 95% CI, 0.30-0.50; P < .001), and the median rPFS was not reached in the enzalutamide arm vs 19 months in the placebo arm. Benefit with enzalutamide was observed across prespecif ied subgroups, with similar benefit regardless of disease volume (ie, low vs high) and prior docetaxel use. Superiority of enzalutamide vs placebo was also shown in key secondary end points, including time to prostate-specific antigen (PSA) progression, time to initiation of new antineoplastic therapy, PSA undetectable rate, and objective response rate.11

From the 5-year data that was presented at ASCO 2022, we see that many of these men are now being treated successfully for 5-plus years, still on drug, and still going where medians havent even been reached. This is phenomenal for our patients. It emphasizes the need for survivorship, Armstrong said.

The 5-year data come from the updated OS analysis of the phase 3 ENZAMET trial (NCT02446405), which randomly assigned 1125 men to receive testosterone suppression plus open-label enzalutamide (n = 563) or a standard nonsteroidal antiandrogen therapy (ie, standard-care group; n = 562).12 Prior to randomization, up to 12 weeks of testosterone suppression and 2 cycles of docetaxel were allowed. At a median follow-up of 68 months, the HR for death was 30% lower among the enzalutamide arm vs the standard care arm. No major differences were found in enzalutamide efficacy across subgroups. Although benefit was most apparent for patients with low-volume mHSPC not deemed to require docetaxel, patients with synchronous high-volume mHSPC necessitating docetaxel still showed benefit. Exploratory analyses suggested additional benefit with triplet therapy, adding enzalutamide to testosterone suppression and docetaxel.12

Apalutamide was approved in mHSPC based on data from the phase 3 TITAN trial (NCT02489318), which randomly assigned 1052 men with mHSPC to receive apalutamide plus ADT (n = 525) or placebo plus ADT (n = 527).13 At the final OS analysis, which included a median follow-up of 44.0 months, the median treatment duration was 39.3 months with apalutamide, 20.2 months with placebo, and 15.4 months with crossover.

Apalutamide vs placebo reduced the risk of death by 35% (HR, 0.65; 95% CI, 0.53-0.79; P < .0001) and by 48% when adjusting for crossover (HR, 0.52; 95% CI, 0.42-0.64; P < .0001). The median OS was not reached in the apalutamide arm vs 52.2 months in the placebo arm. Patients who crossed over were analyzed as part of the intention-to-treat population in the placebo plus ADT group. At 48 months, the OS rates were 65.1% for patients who received apalutamide and 51.8% for those who received placebo. Updated analyses of secondary end points based on the f inal data cutoff showed apalutamide plus ADT delayed second PFS and castration resistance (P < .0001 for both).13

Data from the phase 3 LATITUDE trial (NCT01715285) supported the approval of abiraterone acetate for patients with mHSPC. Investigators randomly assigned 1199 patients with mHSPC to receive abiraterone acetate plus prednisone and ADT (n = 597) or matching placebo plus ADT (n = 602).14 Patients had not received prior chemotherapy, radiotherapy, or surgery for metastatic prostate cancer and were stratified based on the presence of visceral disease and ECOG performance status. There were 2 primary end points: OS and rPFS.

At the final OS analysis, which was performed after a median follow-up of 51.8 months, 618 deaths had occurred (275 patients in the abiraterone arm and 343 in the placebo arm). Patients in the abiraterone arm had a significantly longer OS compared with the placebo arm (53.3 months vs 36.5 months; HR, 0.66; 95% CI, 0.56-0.78; P < .0001). Analysis of OS by subgroups found an OS benefit across most subgroups, with the exception of those with an ECOG performance status of 2 and those with a Gleason score below 8. The final analysis did not include a reanalysis of the rPFS, which was 33 months (95% CI, 29.6-not reached) in the abiraterone arm versus 14.8 months (95% CI, 14.7-18.3) in the placebo arm (HR for radiographic progression or death, 0.47; 95% CI, 0.39-0.55; P < .001) in the preplanned interim analysis.14

With many novel AR-targeting therapies to select from, choosing the best one for each patient can pose a challenge for physicians. From the medical oncology perspective, I spend a lot more time taking a good medical history than maybe I was doing when there were fewer options. Especially when I meet a new patient for the first time, I spend a [significant] amount of time taking [a detailed] cardiovascular history, but also general medical health history, MaryEllen Taplin, MD, said. She explained that she looks at factors such as exercise tolerance, baseline respiratory status, and whether patients have had any falls over the past 2 years because these provide clues that help her select the best drug for each individual patient.

If I have a patient who is [older], [is] relatively sedentary, and had a fall 6 months ago, I might shy away from enzalutamide. But 1 of the other 3 choicesapalutamide, darolutamide, or abirateronemight be better for that particular patient. Ill put in the prescription and try to get the prior authorization and copay information based on that, she said. Regarding abiraterone acetate, Taplin said she would avoid it in patients with a compensated cardiac status and diabetes or trending toward diabetes.

In those with a condition such as congestive heart failure, she said, the risk of fluid retention is a contraindication in her opinion, and for patients with diabetes, she has concerns that the concomitant prednisone would affect patients glucose tolerance. For patients who are good candidates for any of the available agents, the panelists noted that decision-making usually revolves around finances. Once you find out what the co-pay is when you submit that prescription, you want to make sure your patient can afford their medication, Tanya B. Dorff, MD, said. Armstrong agreed and noted that costs among these agents may vary considerably. Paradoxically, abiraterone acetate is generic, but it has some of the hardest co-pays because there are very few assistance programs for it. Darolutamide might be easier because of co-pay assistance [access], he said.

He also suggested that COVID-19 vaccination may factor into decision-making with use of abiraterone acetate because of its concurrent administration with prednisone. A small dose of physiologic replacement prednisone would impair the vaccine efficacy, but we dont have a lot of great data there, he said.

Although mHSPC is generally considered an aggressive prostate cancer, it is still a heterogeneous disease that requires an individualized treatment approach to optimize outcomes. Patients who tend to do worse are those with high-volume, de novo metastatic disease, which is different from those who also have metastatic disease but happen to [have a recurrence] years later and theyve finished treatment, Pedro C. Barata, MD, MSc, said. He noted that patients who tend to do worse have been shown to benefit from treatment intensification approaches, such as a triplet regimen that adds docetaxel and an AR-targeted therapy to ADT, as well as strategies such as concomitant radiotherapy of the primary tumor.

To ensure he identifies patients who would benefit from treatment intensification, Barata said he sequences all patients up front. When I have [a patient with] an aggressive molecular profile, it makes me think about treatment intensification at that point, he said. Another trigger he noted is a low PSA level. Its not concurrent with the amount of disease that you see, he said.

During the discussion, Armstrong explained that an analysis of the ARCHES study found that many patients receiving enzalutamide had radiographic progression despite not showing PSA progression, a finding he noted that could be applied to any AR therapy.15 Were all used to lying back and not doing imaging very often when you see that PSA [level] go down. But we saw that approximately one-third of patients with imaging showing progression at soft tissue or new bone metastasis didnt have any rise in PSA [level] at all, and thats kind of a scary thought, he said.

Barata noted that the next step will be identifying all the patient subgroups who would benefit from treatment intensification approaches such as triplet therapy, as well as which intensification approach may be best suited to each subgroup. Ongoing studies are anticipated to help shed light on these areas.

Read this article:
Novel AR-Targeted Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Which One to Choose - OncLive

TYSON FURY has backed and will continue working with the controversial doctor the British Boxing Board of Control are investigating in the wake of Conor Benns failed drugs test.

Before Dr Usman Sajjad started working with 26-year-old Benn, he gave an extensive explanation on how to evade testing on the Quality Shot podcast.

4

4

4

And he claimed "80 to 90 per cent" of elite boxers are taking a range of drugs to cheat.

Sajjad - who has not been implemented in any wrongdoing - has also spoken at length about the male menopause and how testosterone replacement therapy can be used to fight it.

But his Instagram account and personal website were deleted around October 4 - just as the news of Benns failed test was breaking.

But the 34-year-old Gypsy King has vowed to stand by the GP who the BBBofC are now investigating.

Fury told YouTube boxing channel IDBoxing: "Usman is a good guy.

"I have known him for about a year and he works with quite a lot of boxers and whatever happens I would definitely say it has nothing to do with Usman.

"Usman will be working with me for my next fight, I trust him 100 per cent."

Fury was in Doncaster on Saturday night to watch his brother Roman make his professional boxing debut with a promising win.

JOIN SUN VEGAS: GET A FREE 10 BONUS WITH 100s OF GAMES TO PLAY AND NO DEPOSIT REQUIRED (Ts&Cs apply)

And he explained that Dr Usmans role in his camp would be that of a personal GP for a training camp and would help him with anything as simple as a common cold or an injury affecting him.

Sajjads baffling revealing comments, that remain widely available online, were: "If you are an elite level boxer, you know, pay-per-view, world class, European level, 80 to 90 per cent are doing it (drugs) from what Im seeing.

"When I say doping, its not just steroids. Youve got IV fluid infusion after weigh-ins, youve got diuretics, youve got growth hormones, youve got testosterone replacements.

"In terms of excuses, I dont really believe them. Athletes know whats going to happen if they fail."

Sajjad went on to detail how the different testing systems work - with limited funding - and claimed only an idiot gets caught.

He said: "A lot of times in how the drug testing system works, a lot of the fights in the UK, its all urine testing.

"You have to be an idiot to fail a drug test in England, because urine testing is just 72 hours (most drugs are out of your system within three days).

"You would have to take drugs two to three days before you fight.

"The urine test is after a fight. Whereas the one that trips up a lot of athletes is if you sign up to the random drug testing, which WADA (the World Anti-Doping Agency) do.

"They will track you where you are and can turn up to your house whenever and do a blood test. With a blood test, they can catch things that have been there a month.

"However you can get around the random drug testing, because between the hours of 11pm and 7am, they are not allowed to come to your house.

"A lot of athletes can take fast-acting testosterone or growth hormones which can only be in your body for seven to eight hours.

"You could take it at 9-10pm and it would be out of your system by 7am. Theres ways to get around it. A lot of tricks."

4

Visit link:
Tyson Fury to continue to work with controversial doctor Usman Sajjad despite probe after Conor Benns f... - The US Sun

Cork woman Jess N Mhaolin was just 27 years old when she went into menopause.

Jess had always had trouble with her periods as a teenager, she would miss days of school because of the debilitating pain.

The first time I remember being in hospital because of my periods, I was about 15, she told RSVP.

The doctors thought it was my appendix. Then they found ovarian cysts on the ultrasound. There was very much the attitude that Id grow out of it.

Read more: Limerick mum says hormone replacement therapy has changed her life after menopause

In her 20s, Jesss symptoms got worse, but she still felt like she wasnt taken seriously by doctors.

I had a consultant tell me to go away and have a baby and that would sort it out, she said. I changed consultants I dont know how many times. A few people said it might be IBS so I tried a low FODMAP diet. That didnt work. I tried natural remedies, I tried yoga, I tried different painkillers. None of it worked.

Around 2017, Jess was finally diagnosed with endometriosis, a condition that causes cells similar to the lining of the uterus to grow outside the uterus. She was put on a treatment that put her system to sleep.

In theory, that sounded great, because I wasnt getting periods anymore so I wasnt in pain, admitted Jess.

In reality, it was shutting down my hormone centre. I couldnt regulate my temperature. I was nauseous all the time. I was severely bloated. I was having terrible mood swings.

The next step for Jess was to go through surgical treatment and during this stage, doctors discovered problems with her ovaries. She had to have emergency surgery to have her right ovary removed because there was a growth on it, and her left ovary had stopped working because it was covered in adhesions.

She went to a specialist surgeon in the UK to have treatment on the left ovary but when she was there, she was given some devastating news.

During my scan, the consultant basically stopped what he was doing, sat me down and explained that my left ovary had practically shut down, Jess added.

He asked me if I had suffered menopausal symptoms. I had been experiencing them but Id been through so many operations that I thought it was part of the recovery process.

An hour later, Jesss surgeon gave her her options: but the most practical one was a full hysterectomy.

He gave me some time to think and I remember standing in the middle of Harley Street in London, just crying, she recalled. I had this whole future mapped out in front of me in my head. I thought Id be settled at 30, be buying a house and probably having a baby with someone.

All of a sudden Im 27, in a country that isnt home, being given this devastating news. It was like someone had taken a piece out of my heart that I was never going to get back.

Jess went through with the hysterectomy, but her road hasnt been easy.

Most of my friends are at the age now where they are having their first or second child, or theyre pregnant, she continued.

Im not in a relationship. Part of that is by choice, because I'm married to my job. But part of it is: How do you approach the subject of not being able to have kids with someone? Do you tell them straight away? Do you tell them a few dates in?

Now 30 years old, Jess struggles with the side effects of menopause, but hormone replacement therapy has really helped.

Im on oestrogen and testosterone gel, and it makes such a difference. If I forget to use it or I dont use enough, I would feel towards the end of the day that I would start to get anxious, the brain fog would begin and I would get hot flushes.

My mum is actually going through menopause at the same time as me, so I can talk to her about it which is comforting but also sad.

The Government policy advisor said she is happy to share her story because she wants to help other women.

I thought menopause was something that happened to you when you were maybe 55, when youd had your kids, she said. If I had known that I was having menopausal symptoms before that last scan, maybe I would have had enough time to freeze my eggs. Its hard to know, and I could drive myself mad thinking about it.

Women can get menopause in their 30s for various reasons, so its important to know the symptoms and always advocate for yourself.

Visit The Menopause Hub's website here for more information.

Get the latest RSVP headlines straight to your inbox for free by signing up to our newsletter

READ MORE

Original post:
Cork woman felt like she lost part of herself after going into menopause aged 27 - RSVP Live

Dear Dr. Roach: My 75-year-old husband was frustrated with not being able to retain an erection. He talked to his doctor about it, and she prescribed 200 mg of testosterone cypionate, which he would inject into his bottom once a week. He did this for four months, and then had a severe bilateral stroke (as in, he does not know where he is, what happened to him, cannot read or write, cannot walk, etc.).

After spending two weeks in the ICU, he went to a rehabilitation hospital for three weeks. The hematologist there told me his hemoglobin level was up to 20, and there was no reason a 75-year-old should have been prescribed testosterone when it can elevate his hemoglobin so much.

What are the normal protocols for testosterone with older men? Could his testosterone injections have led to his stroke?

D.H.

Dear D.H.: Testosterone replacement therapy is commonly prescribed to men in their 70s and 80s. Elevations of the hemoglobin levels are certainly well-described, but levels above normal only happen about 1% of the time. Experts recommend checking a blood count to look for these elevations three to six months after starting treatment. Testosterone should be stopped if the hemoglobin level is above normal.

Sometimes, there are other causes for the hemoglobin to go up, but a rise that high, when he had never had it before, makes it seem very likely to me that the testosterone was the cause. A hemoglobin level that high, from any cause, is a risk for stroke and heart attack. It is very possible the testosterone prescription led directly to the stroke.

I am publishing this in the column so that men who are taking testosterone know they should be periodically tested for this unusual complication.

Dear Dr. Roach: I had carpal tunnel surgery two years ago. I now have trigger fingers in my index and ring fingers. I had cortisone injections but that didnt cure it. I, at one point, was not able to open my fingers. Now, my fingers are really stiff, and I cant bend them. Surgery was suggested. Im hesitant, because Im wondering if this will get better on its own with exercises.

J.T.

Dear J.T.: Trigger finger is caused by the tendon getting stuck inside one of the pulleys of the hand. To the best of my knowledge, carpal tunnel surgery doesnt predispose to trigger finger, but there are some conditions that put people at risk for both conditions. Initial treatment of trigger finger is conservative, with splinting and anti-inflammatory drugs.

If that doesnt work, injection of cortisone by a hand surgeon is usually successful.

Most of the hand surgeons I know will try injection three times before recommending surgery. Unfortunately, postponing surgery too long can lead to the finger getting a contracture, where it will not straighten at all.

Readers may email questions to ToYourGoodHealth@med.cornell.edu.

Visit link:
Dr. Roach: Testosterone injections most likely led to severe stroke - Detroit News

A few months ago, a friend of mine in her early 40s said she was having hot flashes, mood swings, and a lower sex drive. She wondered if she could be experiencing symptoms of menopause. Youre too young, I thought. But, as it turns out, shes not. After speaking to her OB/GYN, my friend realized she is experiencing perimenopause symptoms of menopause without actual menopause (which is marked by a year without a menstrual cycle). She learned it can start as early as your mid-30s (though mid-40s is more common).

It turned out my friend wasnt alone in her surprise and lack of knowledge of this hormonal phase. Earlier this year, Bonafide, a wellness company that makes non-prescription products to help alleviate common health issues in women, came out with their Second Annual State of Menopause Survey. The goal was is to shed light on the need to destigmatize talking about menopause and perimenopause for that matter. The company surveyed more than 2,000 women ages 40 to 65 about various menopausal-related things, from their knowledge about the process to their general feelings and sentiments surrounding it.

Twenty-five percent were not aware of when perimenopause typically starts while 31% did not know their treatment options. In addition, just 28% knew how to care for themselves during perimenopause before it started.

Ahead, womens health experts weigh in and unpack what, exactly, perimenopause is and how you can best be prepared for it.

Perimenopause begins years before actual menopause, OB/GYN Kecia Gaither, tells TZR in an email. It reflects a period of time when the ovaries begin to gradually make less estrogen and when no more eggs are released by the ovaries. Perimenopause ends when women have gone a year without having a menstrual cycle. She also says its important to note that each woman is different and, as such, perimenopause will occur at different ages. However, in general, perimenopause typically begins for a woman in her 40s. Again, this transition period varies from woman to woman from months in some to a decade or so in others.

Dr. Sherry Ross, womens sexual health expert, and author of she-ology and she-ology the she-quel, agrees. This hormonal change typically happens within a couple years of menopause, which usually happens around age 51, she tells TZR in an email. But for some, it can happen much earlier. Every decade brings about some emotional and physical change, but for women, the decade of ones 40s may pack the biggest punches of all.

Echoing Gaither, Ross says that every woman will experience perimenopause differently, including when the hormonal storm begins. There is also evidence that women who smoke, have a family history of early menopause, undergo treatment for cancer with chemotherapy or radiation, or have a hysterectomy (without removing the ovaries) may experience perimenopause earlier than other women, she explains.

Symptoms of perimenopause are similar to menopause, so you may wonder what the difference is. Perimenopause is a transitional period before and after a woman is still menstruating, but beginning to experience symptoms, Dr. Tamika K. Cross, OB/GYN and pH-D Feminine Health advisor, tells TZR in an email. While menopause is defined as 12 months without a menstrual cycle.

Ross says symptoms may include:

And not every woman will have symptoms, Cross says. This just varies with genetics, but more often than not, there are at least a few of the symptoms experienced, although the severity may vary.

Gaither says diagnosis of perimenopause is made clinically by presenting symptoms and getting your hormonal levels (FSH) checked. Although there is no treatment, per se, she says there are many options to help alleviate symptoms.

It depends on each womans specific situation and medical history, Cross explains. Its important to talk with your doctor to see what options are best for you. Ross also points out that different symptoms will require different treatments.

That said, there are some avenues to explore for specific concerns. For instance, for heavy and irregular periods, The best treatment for this tends to be with hormones, such as low-dose oral contraception (as a way to control erratic periods), says Ross. Experiment with different pills in order to find the one with the least side effects. Other options include cyclic progesterone, IUDs with progesterone, hormone replacement therapy (HRT), and non-hormonal alternatives, such as acupressure and herbal therapy. Ross says your healthcare provider can explain the ins and outs of these, and what may work best for you.

For the dreaded hot flashes, Dressing in layers and staying in cool temperatures are the first steps in dealing with hot flashes, explains Ross. Air conditioning is your friend! Plan ahead. Bring a cooler with ice for your hands or feet. If you know that hot beverages, spicy foods, red wine, and hot climates bring on hot flashes, avoid them (if possible). And she says herbal remedies (more on those below) may include black cohosh and other traditional Chinese medicine. Acupressure may help with mild hot flashes, as well, she adds.

For mood swings, Antidepressants are effective in controlling depression, anxiety, and panic attacks, and a therapist may also give added support, says Ross. And, of course, exercise, the elixir to all. When you exercise, theres a natural release of mood-boosting endorphins and serotonin, the feel-good hormones that your body can naturally produce.

For those experiencing low sex drive, low libido, and/or vaginal dryness, Testosterone therapy may be helpful for a low libido, says Ross. For help with vaginal dryness, lubricants (such as KY and extra virgin coconut oil) are a good and affordable investment. Sometimes, once you gain control of the annoying hot flashes, irregular bleeding, and emotional distress of perimenopause, sexual interest is regained and your libido is rescued. She also points out that there is an FDA-approved medication called Addyi, known as the pink pill for women. It works on neurotransmitters in the brain, including serotonin, dopamine, and norepinephrine, all found to be involved with sexual desire.

When it comes to trying to combat perimenopause or at least manage its effects better a great initial plan of attack against symptoms is with a thoughtful and healthy lifestyle. A well-balanced, and colorful, diet of fruit, vegetables, whole grains, and nuts and a limited amount of saturated fats, oils, sugar, and dairy will help, says Ross. Drinking water, warm or hot, helps relax the uterine muscles, too. In fact, drink as much water as possible, 2-3 liters a day, to help minimize water retention and bloating. She adds that you can also try consuming water-based foods, including berries (strawberries, blueberries), celery, cucumber, lettuce, and watermelon. Adding ginger to hot water is another useful remedy, she says. And find an exercise routine that will keep you interested well beyond this perimenopausal period, too.

If diet and lifestyle changes dont curb the symptoms of perimenopause, Ross says there are some safe alternatives to help you get through your day. There are many scientifically studied herbs and vitamins that can help manage the symptoms, so you can avoid prescription medications given to you by your healthcare provider, she explains. Passion flower extract, chasteberry, royal jelly, ashwagandha, and maca root are some of the more researched herbs that can actually improve your symptoms and life. She notes that herbs are not FDA-approved like pharmaceutical medications, but that using a well-regulated manufactured herbal supplement can achieve the same effects as prescription medication. And they will safely treat hormonal unrest caused by perimenopause, she adds. Vitamins are important, too. Ross suggests taking calcium, vitamins E and D, thiamine, magnesium, and omega 3-fish oil to help relieve the period bloat and swelling.

Getting a good nights sleep is imperative, too. Hot flashes can mess with ones sleep patterns, Ross explains. First and foremost, avoid excessive caffeine and alcohol (if you dont care to give it up entirely). Seriously, consume your favored vices in moderation. Theyre not bad, per se its just better to have less. She recommends one large cup of coffee in the morning and not more than three to four alcoholic beverages a week (if at all). Set a regular bedtime, limit your liquids after dinner (so you need not take a midnight bathroom break), and try a warm bath before bed, she adds. And is your mattress comfortable and supportive? If not, make it so. Lastly, put your electronic devices (phone included) far from your night table. You dont need the lure (or the light) of them at bedtime.

And acupuncture is another way to manage perimenopauses symptoms. This ancient Chinese treatment for maintaining health and vitality by balancing energy flow works for many medical conditions, says Ross. For women especially, headaches, lower back pain, and menstrual cramps are helped through acupuncture. Even though the studies are not conclusive, hot flashes and heart palpitations may improve with acupuncture treatment, too.

But in addition to the above, getting psychological support and reassurance from others is also key. Sometimes, what we need most is a thorough understanding of exactly what is happening physiologically, if only to realize that what were going through is completely normal, says Ross. Therapy and support groups are often helpful in navigating this hormonal obstacle course.

Lastly, Ross says that women in their 40s (give or take) who are experiencing unusual hormonal symptoms need to find a healthcare provider to help them navigate the changes caused by perimenopause. There are simple treatment remedies, along with reassurance, that these are natural symptoms that need to be taken seriously not just by the patient, but also by the healthcare provider.

(Stay Up To Date)

Become A Style Insider

Join The Zoe Reports exclusive email list for the latest trends, shopping guides, celebrity style, and more.

Excerpt from:
What To Know About Perimenopause, And How To Manage Symptoms Once They Kick In - The Zoe Report

Hormone changes affect everyone, yet 73 percent of women in the U.S. do not seek medical help for menopause, according to the 2021 State of Menopause Study by Bonafide. These changes are one of the top reasons women come to see me. As a functional medicine doctor, Ive helped women manage this stage of their lives for more than 20 years. Its the visible symptoms that bring them in: night sweats or loss of hair. However, there are silent results of changing hormones that are equally as important to address. Before I explain a solution, I want to walk you through why women experience those symptoms, the different types of symptoms, and finally, what you can do to combat some of the issues.

In typical cases, hormones start to change in your early forties. Most women will feel like they have estrogen dominance symptoms. This is not because they make too much estrogen, but rather their ability to make enough progesterone which counters the effects of estrogen slows down. The symptoms may be heavy, irregular, and painful periods, breast tenderness and moodiness, insomnia, painful sex, vaginal dryness, and loss of libido. Symptoms tend to be worse, especially just before they start their period.

Several years later, usually between 48-52 years old, woman transition to menopause. This is a particularly difficult time as women may start having heavy periods off and on, worsening mood swings, highs and lows with irritability, insomnia, hot flashes, night sweats, weight gain, painful intercourse, vaginal dryness, urinary frequency, loss of libido, hair thinning and loss. Then, when a woman hasnt had a period for a year, she has officially entered menopause.

When it comes to hormone changes, women see me for two specific reasons: feelable and invisible symptoms. Feelable symptoms are the ones you can physically feel. These affect your daily life. They can range from hot flashes to night sweats, insomnia to mood swings, irritability to memory loss, and even weight gain and hair loss.

These are symptoms you cannot feel but greatly impact your life. Hormone changes can wreak havoc on your bones and muscles in the form of osteoporosis or osteopenia, leading to hip fractures which can be life-changing. Your cognitive health can decline as well as increasing fears of memory loss and Alzheimers dementia. You may experience heart disease in the forms of high blood pressure and high cholesterol which are leading causes of strokes and heart attacks. Another silent symptom is an increase in insulin resistance leading to belly fat weight gain and diabetes.

Many women feel they just have to deal with all of these changes. That could not be further from the truth. The information Im about to provide can be an absolute game changer in your life.

Bioidentical hormone replacement, as opposed to synthetic hormone replacement, is using hormones like estradiol, that your body recognizes as biologically identical to the hormones that you naturally make. Synthetic hormones, like the ones found in Premarin, come from a horses urine and are not identical to what your body naturally makes.

The old thoughts that hormones are dangerous for you are based on studies done on synthetic hormones that are bad for you. However, Ive found that bioidentical hormones are recognized by your body and it reacts accordingly.

I use specialized testing to look at how a woman is breaking down estrogen. The goal is to make sure her body can process the hormones properly. The next step is to balance hormones using bio-identical estrogen, progesterone, and testosterone. Once a balance is established, there is lab testing before and during to make sure the dosage is correct. Of course, I have follow-up visits to make sure symptoms have improved. When you combine all this together, not only do you not have to live with these menopause symptoms, but you can safely navigate this period of your life and improve longevity and vitality for years to come.

If hormone replacement therapy is done properly, it can reduce the risk of heart attacks, strokes, Alzheimers dementia, and broken hip bones. Not to mention improving quality of life, improving libido, vaginal dryness complaints, insomnia, hot flashes/night sweats, mood stabilization and decreasing risk of depression.

Clinical trials, including Heart and Estrogen/Progestin Replacement Study I and the Womens Health Initiative, have shown that conventional hormone replacement results in increased thrombotic events, an increased risk of breast cancer, and dementia. However, biodentical hormone therapy used by functional medicine doctors do not carry these increased risks.

Using transdermal creams or patches or bioidentical estrogen hormones and progesterone, not progestin, does not afford the same risks. This is why current and more advanced hormone replacement therapy is safer.

I have found additional ways to help my patients navigate their changing hormones. However, you would want to consult your doctor if you have any questions about trying these yourself.

In addition to bioidentical hormone replacement therapy, there are things you can do to limit your symptoms and yes, it does start with your diet. I recommend limiting your processed foods. Essentially, this is anything that comes out of a box or a bag. Try to eat about 3 to 4 cups of vegetables, 1 to 2 servings of fruit, healthy fats, and proteins every day.

Get a good nights sleep, exercise, and make sure you incorporate self-care, like a bath, sauna, or massage to alleviate stress. I also recommend taking magnesium, taurine, NAC, and B complex vitamins to help mitigate some symptoms.

You can help your bone density by doing weight-bearing exercises or joining a club called OsteoStrong. There are some supplements I recommend like Ossopan MD. Its a highly absorbable form of calcium plus essential minerals that you can get from a functional medicine doctor along with Vitamin K2 and D3.

If youre concerned about heart disease, you should limit simple sugars, basically anything white like bread, pasta, candy, and ice cream. The foods I recommend are whole food oils like avocado and olives, proteins, and foods found in the Mediterranean diet. I will also recommend Omega-3 fatty acids, magnesium, CoQ10, niacin, bergamot, berberine, alpha lipoic acid, and taurine based on a specialized lipid study. HITT workouts and intermittent fasting can also help lower your risk for heart disease. Always consult with your doctor first.

The final invisible symptom I would like to address is cognitive decline. In addition to exercise and sleep, I highly recommend Grain Brain by Dr. David Permutter. You can also find other suggestions in my previous article about improving cognitive function.

Hormone changes are inevitable. I strongly recommend arming yourself with information and asking lots of questions. You may have to live with changing hormones, but that does not have to adversely change your life.

See original here:
The One Thing This Doctor Says Is A Game Changer When It Comes To Hormones And Aging - TravelAwaits

Strictly Come Dancings Head Judge Shirley Ballas has forged a glittering career to date and is gracing our screens once more, as the latest celebrities take to the dance floor for a new Strictly series.

But, as Shirley explains in her own words, its not all baubles, bangles and beads. Behind the scenes, Shirley has been managing her ongoing menopause journey, and she describes the early part of her experience as one of the darkest periods of her life.

Following her own difficulties, Shirley decided to speak out to help other women and has now joined the new Menopause Your Way campaign with QVC.

According to research commissioned by the campaign, only one in 10 women feel prepared for the landmark change. Of those who believed they knew what symptoms to expect, two in five still felt they did not have a clear understanding of how to manage them.

Here, Shirley opens up to Good Housekeeping about her experience with menopause, how she found support and where she is on her journey today.

I didnt know what was wrong to begin with, I didnt put the menopause tag on it. It started with all those sweats and the bad skin and generally feeling low all the time. It was overwhelming.

I can only say it feels like a volcano in your tummy, and it goes all the way up and starts erupting. You start sweating, you're uncomfortable, you're agitated. I didn't want to go out anymore, I was struggling to go to work. Doctors gave me anti-anxiety medication and then they gave depression medicine, nobody understood it.

Your body starts to change during menopause, it gets a little more rounded because it starts to protect itself and thats absolutely fine. But at the time, I didnt know why I was gaining weight when Id always been physically fit.

My skin was drying out, my nails were chipping, I felt dehydrated all the time and I had no libido.

It was my son, Mark, who first sat me down and said, Okay, lets talk about it. He was willing to take a whole afternoon to listen to me. He introduced me to his doctor in the United States, where we were living at the time. From there, I started taking bio-identical hormones (an alternative to HRT, hormone replacement therapy) which was life changing.

Allen Berezovsky

Other than my brother taking his own life [Shirleys brother, David, died in 2003 after battling depression], I would say it was one of the other darkest periods of my life. Some women, like my mother, they sail through the menopause, but that certainly wasn't the case for me. I just wanted to get up in the morning and feel better.

Not everyone can take hormones, but I found hormone replacement life changing and I regularly check my oestrogen and testosterone levels with a doctor. Its all about understanding your own body and using a combination of approaches.

Ive always had a healthy way of eating, Ive always exercised. I love yoga and going for a walk in the park. I try to find time for myself, even just half an hour is better than no time at all.

I want women to know that its not all baubles, bangles and beads just because Im seen dressed up in glad rags on a Saturday.

Being on Strictly has given me a platform. I feel like I have a responsibility to try to help women understand what their bodies are going through when they hit menopause at 45 or 50 or whenever they go through it, because early menopause can happen even in your 20s.

I do a lot of work around other causes like cancer and suicide and I feel that menopause is just as a strong conversation that needs to be happening. Thats why I joined the campaign with QVC, to help educate people and move conversations forward.

The key for me is education. This message is not just for women, it's also for men, for workplaces, for families and younger generations. We learn about puberty when were younger, but we dont know about how our bodies will change after that. I think its just as key to understand the whole biological process all the way up until menopause is complete.

If you notice a sudden change in your body, particularly around the age of menopause, then you have to find help. Go and see a doctor because if you start early enough when it comes to taking hormones or accessing support, then it can be a non-frightening experience.

You can also find information to read up on and links for support through the QVC campaign.

We want to help put the message out to help women of all ages and educate the whole family. The people around you need to understand the high and the low moods, the night sweats and whats going on in your body. Dont suffer in silence. Thats the key message, no more suffering.

I would say its ongoing with my hormones but generally, Im in a much better period now than 10 years ago which was horrific. Id say when I was around 57 my body started to balance out.

Of course, Ive been looking forward to the new Strictly series so it's a very exciting period, but Ill still be going to get my hormone levels checked during the Strictly run. Its an ongoing journey.

Shirley Ballas is partnering with QVC UK's Menopause Your Way campaign, to offer reassurance, insight and inspiration to empower women experiencing the menopause.

You can get tickets to join Shirley Ballas for fizz and cake at Good Housekeeping Live in partnership with Dyson on Friday 14 October.

FIND OUT MORE

Read the original post:
Shirley Ballas on her difficult experience with menopause - Good Housekeeping

RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side effects ofKYZATREX to Marius is 1-833-949-5040. The corrected release follows:

Marius Pharmaceuticals, a patient-centric healthcare company, today announced the approval of KYZATREX (testosterone undecanoate) by the U.S. Food and Drug Administration (FDA). KYZATREX is an oral testosterone replacement therapy ("TRT") indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. The approval of KYZATREX provides an important option in treating hypogonadism or more commonly known as, Testosterone Deficiency, which affects approximately 40% of men older than 45 years of age and 30-50% of men with obesity or type 2 diabetes have hypogonadism1. KYZATREX has been approved in three dosage strengths, 100mg, 150mg, and 200mg.

I would like to congratulate our scientific team on this major milestone, and now it is up to our commercial team to make KYZATREX a leading therapy and a go-to brand for millions of hypogonadal men in the U.S. Low Testosterone affects numerous metabolic factors as well as often overlooked, true quality of life, hence annual testosterone testing should be mandatory for men over age 40, remarked Himanshu H. Shah, Chairman of Marius.

KYZATREX is a proprietary oral softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity. The oral delivery method eliminates the risk of application site reactions common with intramuscular testosterone injections as well as potential transference to women or children that can occur with topical testosterone gels and creams. With daily dosing in the morning and evening (with food), KYZATREX more closely mimics the daily rhythm of natural testosterone production compared to long-acting therapies.

With so many men suffering daily effects of Testosterone Deficiency and often abandoning or not electing to get treatment, we see FDA-approved KYZATREX as a newly viable oral option that has demonstrated safety and effectiveness. Further, Testosterone Deficiency is a big blind spot in medicine today and our research will continue to explore the importance of testosterone in both male and female health, commented Shalin Shah, CEO of Marius.

KYZATREX has the potential to become the new gold standard of care for treating patients with hypogonadism. There are at least six million symptomatic men suffering from hypogonadism in the U.S., and over 100 million men globally.

Please see additional Important Safety Information for KYZATREX below.

1 Endocrine Society

About Testosterone and Hypogonadism

Hypogonadism, often referred to as Testosterone Deficiency, is a condition that occurs when the body does not produce adequate levels of testosterone. Primary hypogonadism (testicular failure due to certain conditions) and hypogonadotropic hypogonadism both result in low serum testosterone concentrations. In addition to testosterones widely accepted role in sexual and reproductive function, it also has important roles in numerous other metabolic and inflammatory process and is one of the most common causes of secondary osteoporosis in men. Patients with hypogonadism may experience fatigue, low energy, decreased muscle mass, weight gain, low libido, poor cognition, difficulty sleeping, and other mood disorders, such as depression and anxiety. Because low levels of testosterone can also increase the risk of developing type 2 diabetes and obesity, hypogonadism is a common comorbidity in a broader set of conditions, including type 2 diabetes and Non-Alcoholic Steatohepatitis (NASH).

About KYZATREX

KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males between 18 and 65 years of age with documented hypogonadism, as defined by a below normal serum testosterone level (281 ng/dL) and at least one sign or symptom of testosterone deficiency. In the efficacy population (n=139), 88 percent of hypogonadal men treated with KYZATREX achieved a mean plasma total testosterone concentration (Cavg) over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic (PK) visit of the study at Day 90 (primary endpoint). Based on exploratory endpoints, patients who received KYZATREX reported improvements in quality of life, energy/fatigue, erectile function, intercourse satisfaction, and positive mood. The most common side effect reported in 2 percent of KYZATREX patients was increased blood pressure (2.6%). The safety and efficacy of KYZATREX in males less than 18 years old have not been established.

Please see additional Important Safety Information below, including Boxed Warning for potential increased blood pressure, for KYZATREX.

About Marius Pharmaceuticals

Marius Pharmaceuticals is a patient-centric healthcare company focusing on therapies designed for hypogonadism or Testosterone Deficiency. The companys mission is to improve the functional lives of patients by reducing the downstream effects of Testosterone Deficiency, which include multiple comorbidities, such as type 2 diabetes and obesity. For more information, please visit http://www.mariuspharma.com

Important Safety Information for KYZATREX (testosterone undecanoate)

Use

KYZATREX (testosterone undecanoate) is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions. KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in children. KYZATREX is not meant for use by women.

Important Safety Information for KYZATREX

KYZATREX can increase blood pressure, which can increase the risk of having a heart attack or stroke and can increase risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke.

Do not take KYZATREX if you: have breast cancer; have or might have prostate cancer; are a woman who is pregnant (KYZATREX may harm your unborn baby); are allergic to KYZATREX or any of its ingredients; or have low testosterone without certain medical conditions (e.g., do not take KYZATREX if you have low testosterone due to age).

Before you take KYZATREX, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure or are treated for high blood pressure; have a history of diabetes; have heart problems; have high red blood cell count (hematocrit) or high hemoglobin laboratory value; have urinary problems due to an enlarged prostate; have liver or kidney problems; or have problems breathing while you sleep (sleep apnea).

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking KYZATREX with certain other medicines can affect each other. Especially, tell your healthcare provider if you take: insulin; medicines that decrease blood clotting (blood thinners); corticosteroids; or medicines that increase blood pressure, such as some cold medicine and pain medicines.

KYZATREX may cause other serious side effects including:

Call your healthcare provider right away if you have any of the serious side effects listed above.

The most common side effect of KYZATREX is high blood pressure. Other side effects may include headache, joint or back pain, diarrhea, increased red blood cell count, anxiety, constipation, swelling of the legs, and increased prostate specific antigen (PSA) levels.

These are not all the possible side effects of KYZATREX. For more information, ask your healthcare provider or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Marius by calling 1-833-949-5040.

Keep KYZATREX and all medicines out of the reach of children.See Full Prescribing Information and Medication Guide for KYZATREX.

Media Contact:Lilly Washburn lilly@mariuspharma.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/ba2569ca-0922-4b49-8d68-49424b5e44d4

https://www.globenewswire.com/NewsRoom/AttachmentNg/f825d70b-874a-4cef-9160-429f83bbfc66

Read more here:
CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX, an Oral Testosterone Replacement Therapy - GlobeNewswire

ReportLinker

Global Testosterone Replacement Therapy Market 2022-2026 The analyst has been monitoring the testosterone replacement therapy market and it is poised to grow by $ 402. 87 mn during 2022-2026, accelerating at a CAGR of 3.

New York, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Testosterone Replacement Therapy Market 2022-2026" - https://www.reportlinker.com/p04046949/?utm_source=GNW 1% during the forecast period. Our report on the testosterone replacement therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by initiatives to increase awareness about hypogonadism among population, rise in chronic diseases, and untapped potential in developing countries.The testosterone replacement therapy market analysis includes the product segment and geographic landscape.

The testosterone replacement therapy market is segmented as below:By Product Injectables Topicals Others

By Geographic North America Europe Asia Rest of World (ROW)

This study identifies the rise in novel therapeutic approaches as one of the prime reasons driving the testosterone replacement therapy market growth during the next few years. Also, patient assistance programs and the development of new therapies will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the testosterone replacement therapy market covers the following areas: Testosterone replacement therapy market sizing Testosterone replacement therapy market forecast Testosterone replacement therapy market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading testosterone replacement therapy market vendors that include AbbVie Inc., Acerus Pharmaceuticals Corp., Acrux Ltd., Actiza Pharmaceutical Pvt. Ltd., Antares Pharma Inc., Aytu BioPharma Inc., Bausch Health Co. Inc., Bayer AG, BIOTE MEDICAL LLC, Cipla Ltd., Clarus Therapeutics Inc., Eli Lilly and Co., Endo International Plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Simple Pharma Co. UK Ltd., Upsher Smith Laboratories LLC, and Viatris Inc. Also, the testosterone replacement therapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.Read the full report: https://www.reportlinker.com/p04046949/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

The rest is here:
The Global Testosterone Replacement Therapy Market is expected to grow by $ 402.87 mn during 2022-2026, accelerating at a CAGR of 3.1% during the...